Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, DxS, Expand Cross-license Agreement

NEW YORK (GenomeWeb News) – Epigenomics and DxS have struck a cross-license agreement that will allow both companies to develop and market DNA methylation-based in vitro diagnostic products that use DxS’ PCR technology, Epigenomics said today.

The agreement follows a deal the companies signed in early 2008 that gave Epigenomics worldwide non-exclusive rights to use the Scorpions PCR technology in research and development and in research kits, and which included an option to expand the license to cover use as an IVD.

That agreement gave DxS an option for a worldwide, non-exclusive research and IVD license for intellectual property covering the use of its PCR technology for DNA methylation applications.

Under the new agreement, both companies have executed these option agreements and have sub-licensed their respective technologies.

Epigenomics’ CEO, Geert Nygaard, said in a statement that the option and cross-license agreements give the company “flexibility in the final product design and testing platforms for cancer molecular diagnostic products” marketed by Epigenomics and its partners.